Claims:

1. A compound having the structure:



or a pharmaceutically acceptable salt or hydrate thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:



or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and optionally other therapeutic agents.

4. The pharmaceutical composition of claim 3, wherein the other therapeutic agent is ribavirin, palivizumab, motavizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444, MDT-637, BMS-433771, amiodarone, dronedarone, verapamil, Ebola Convalescent Plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), favipiravir (also known as T-705 or Avigan),T-705 monophosphate, T-705 diphosphate, T-705 triphosphate, FGI-106 (1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinolone-1,7-diamine), JK-05, TKM-Ebola, ZMapp, rNAPc2, VRC-EBOADC076-00-VP, OS-2966, MVA-BN filo, brincidofovir, Vaxart adenovirus vector 5-based ebola vaccine, Ad26-ZEBOV, FiloVax vaccine, GOVX-E301,

GOVX-E302, ebola virus entry inhibitors (NPC1 inhibitors), or rVSV-EBOV or mixtures thereof.

5. The pharmaceutical composition of claim 4, wherein the other therapeutic agent is ZMapp.

6. Use of a compound of claims 1, or a pharmaceutically acceptable salt or ester thereof, for the preparation of a medicament for treating a *Filoviridae* virus infection in a human.

7. The use of claim 6 wherein the *Filoviridae* virus infection is an ebolavirus infection.

8. The use of claim 6, wherein the *Filoviridae* virus infection is a Marburg virus infection.